

### Mid-term recruitment report Quarterly report V6

---

---

#### Publishable Summary

This quarterly report aims at providing detailed information on the progress of the AMYPAD Diagnostic and Patient Management (DPMS) study with a specific focus on the progress achieved during the second quarter of 2020. The report shows the drastic decrease in the recruitment of patients in all eight active sites due to the COVID-19 pandemic.

Recruitment stopped in all sites from the second week of March to the end of April. Starting from May, recruitment has slowly restarted at CHUV, UKK and KI.

As of June 30th, 2020, 763 patients have been included and 558 scans performed (including 12 repeated scans).

At the moment the study includes 204 SCD, 339 MCI and 220 dementia patients. The tracer balance between Vizamyl and Neuraceq has been stable with a use of 48% and 52% respectively

The recruitment will be able to resume in all sites once the situation has stabilized, with an expected delay of 6 months to reach the 900 patients (December 2020 instead of June 2020).

For this reason, an end of study in September 2021 may not allow the future new patients to complete the last visits planned in the protocol before the end of the study. In this frame, a focus on the V1 (3 months) will be made, as this visit represents the primary endpoint of the study. A protocol amendment has been approved in Switzerland to make the subsequent visits optional and being submitted in the other countries.

We however must consider that COVID-19, apart from impacting recruitment, may also impact scanning in the future. Indeed, since there will be many regular clinical practice patients waiting for scans, research scans may be delayed until clinical ones are cleared.

**For more information:** [info@amypad.org](mailto:info@amypad.org)

**Acknowledgement:** This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

